This chart shows the pharmaceutical companies with the most suspension dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most suspension dosed drugs are: TARO HIKMA HARROW EYE NOVITIUM PHARMA AMNEAL BAU…
Which pharmaceutical companies have the most suspension dosed drugs? Read Post »
The 505(b)(2) regulatory pathway provides an attractive avenue for drug developers to bring new products to market by leveraging existing data on approved drugs. This pathway allows modifications and improvements to be made to existing drugs, while pot…
Leveraging 505(b)(2) to Innovate Beyond Existing Drug Patents Read Post »
The development of injectable formulations is a complex and critical aspect of pharmaceutical manufacturing. Excipients, the inactive ingredients in these formulations, play a pivotal role in ensuring the stability, efficacy, and safety of the final pr…
Excipient Use in Injectable Formulations: Best Practices Read Post »
MOVANTIK (naloxegol oxalate) Valinor Patent: 7,056,500 Expiration: Jun 29, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugPat…
Drug Patent Expirations for the Week of June 23, 2024 Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug pat…
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long time needed to obta…
Which pharmaceutical companies have the most SPCs in Italy? Read Post »
MOVANTIK (naloxegol oxalate) Valinor Patent: 7,056,500 Expiration: Jun 29, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugPat…
Drug Patent Expirations for the Week of June 23, 2024 Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug pat…
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired. For a global perspective, see the Drug companies with th…
Which pharmaceutical companies have the most drug patents in Serbia? Read Post »
Annual Drug Patent Expirations for BORTEZOMIB Bortezomib is a drug marketed by Accord Hlthcare, Apotex, Baxter Hlthcare Corp, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hetero Labs Ltd Vi, Hospira, Jiangsu Hansoh Pharm, Meitheal, MSN, Mylan Labs Ltd,…
Get new actionable insights and updates from BiotechBlog
